Back HCV Treatment

EASL 2015: Paritaprevir and Ombitasvir Are Effective for Japanese Patients with HCV Genotype 1b

AbbVie's paritaprevir/ritonavir/ombitasvir coformulation (Viekirax in Europe; part of the Viekira Pak regimen in the U.S.) was highly effective in curing hepatitis C without the accompaniment of dasabuvir (Exviera) in Japanese people with genotype 1b hepatitis C virus (HCV) infection in the GIFT-1 trial, researchers reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna.

alt

Read more: